Appointment of Cost Auditor: The Board of Directors based on the recommendation of the Audit Committee, has approved the appointment of M/s Aatish Dhatrak & Associates, a Partnership ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.6 pts less than Nifty Microcap 250 and 12.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Coral Laboratories' board, at its May 30, 2025 meeting, approved audited standalone financial results for Q4 and FY ended March 31, 2025, with the statutory auditor issuing an unmodified opinion. Revenue from operations surged 37% YoY to ₹11,500.53 lakhs (vs ₹8,366.04 lakhs), while profit after tax jumped 53% to ₹2,415.56 lakhs (vs ₹1,578.90 lakhs), lifting EPS to ₹67.61 (vs ₹44.19). The board recommended a 15% final dividend (₹1.50 per share on ₹10 face value) subject to shareholder approval. Additionally, the company appointed M/s SARK & Associates LLP as secretarial auditor for five years (FY26–FY30), M/s S K Doshi & Associates as internal auditor for FY26, and M/s Aatish Dhatrak & Associates as cost auditor for FY26.
Strong double-digit growth in both revenue and profit signals healthy operating momentum and improved profitability, which is likely to be viewed positively by investors. The dividend announcement and clean audit opinion further reinforce shareholder confidence, though the small free-float and limited trading liquidity may dampen immediate stock price reaction.